|
|
Home > Healthcare > Pharmaceutical > Drug Discovery
SPECIAL REPORT: Understanding Treatment Dynamics and Needs in Juvenile Idiopathic Arthritis
|
| Published Date:
June 2009
Published By:
Decision Resources
Page Count:
25
Order Code:
R55-649
|
|
|
|
Introduction
Although interviewed thought leaders acknowledge that available biological therapies have greatly
improved treatment of juvenile idiopathic arthritis (JIA)—the most common rheumatic disease
in children—they do not hesitate to point out unmet needs and remaining drug development
opportunities in this field. When current treatments fail, severe disability and even death can result.
The heterogeneous nature of JIA leaves room for drugs that target new targets while meeting the
particular needs of the pediatric population.
Questions Answered in This Report
- JIA is an umbrella term for seven distinct diagnoses. How are the various JIA subtypes defined?
How are they diagnosed? How does their treatment differ?
- The drugs used in the treatment of JIA are identical to those used in adult rheumatic diseases.
What are the first-line therapies for JIA? What factors drive prescribing decisions? How safe
and efficacious are these treatments in children?
- Not all JIA patients are sufficiently treated with available therapies. Which specific unmet needs
remain? What agents are in development for JIA? How will these agents fit into the treatment
patterns for these diseases? What do thought leaders say about emerging agents?
Scope
- Overview of JIA: Oligoarthritis; polyarthritis; enthesitis-related arthritis; psoriatic
arthritis; systemic JIA; diagnosis of JIA.
- Epidemiology: Ten-year forecast for United States, France, Germany, Italy, Spain, United
Kingdom, and Japan.
- Current therapies: nonsteroidal anti-infl ammatory drugs (NSAIDs); corticosteroids;
methotrexate; tumor necrosis factor-alpha (TNF-á) inhibitors; Orencia; Kineret; Rituxan.
- Emerging therapies: Rilonacept; canakinumab; tocilizumab.
- Opportunities in JIA: Qualitative market outlook for current and emerging agents; unmet
needs.
- Primary research: Thought-leader interviews from the United States, France, Germany,
and the United Kingdom.
|
Similar Products
• Antidiabetics in Australia Market Forecast
Published Oct 2009 by Datamonitor
• Plunkett's Health Care Technologies Overview 2010 (Summary)
Published Oct 2009 by Plunkett Research, Ltd.
• Pipeline Insight: Disease Modification in Rheumatoid Arthritis - New drug targets compete in crowded market
Published Oct 2009 by Datamonitor
• Commercial Insight: Parkinson's Disease - Japan and Europe to drive total market growth
Published Oct 2009 by Datamonitor
• Commercial Insight: Antidepressants - Novel mechanism offers hope in depressed market
Published Oct 2009 by Datamonitor
• Parkinson's Disease Market Forecast
Published Oct 2009 by Datamonitor
• Orphan Drug Strategies
Published Oct 2009 by Datamonitor
• Pipeline Insight: HIV - The Age of Convenience
Published Oct 2009 by Datamonitor
• The World Market for Addiction Disorders, 2009 - 2016
Published Oct 2009 by Spectra Intelligence
|
|
|
|
0 items
